Cross-Category Violations Rooted in Process Failures

This category collects four cases that either fall outside categories 01–07 or simultaneously satisfy multiple violation types. Drug classes span osteoporosis treatment, allergy medication, metabolic drugs, and Kampo formulas, yet one structural problem runs through all four: the internal review and approval process for materials and lectures failed to function, or outdated resources continued to be used after the regulatory transition deadline had passed. Case 08-02 is documented as fitting every category from ① to ⑥, meaning a single lecture contained overlapping failures—unapproved indications, unsupported claims, exaggerated language, and insufficient safety information. Case 08-03, using the phrase "an abnormal situation" to incite anxiety, triggered simultaneous violations of both other-company disparagement and exaggeration rules, placing it at the intersection of category 06 and this one. Even when a case is labelled miscellaneous, the questions a reviewer must ask remain the same as in every other category.

Mio"Yui, what was your first impression when you looked at vol. 8?"

Yui"Honestly, the label 'miscellaneous' bothered me. Only four cases, completely different drug classes—I kept wondering why this needed its own category at all."

Mio"That sense of disconnect is actually the key to understanding this category. Of the four cases, which ones have a process failure as the starting point, before you even look at the content?"

Yui"Case 08-02. The responsible department's review was insufficient before the lecture went ahead. And 08-04—using an outdated package-insert format—that's a materials management problem, not a content problem."

Mio"Exactly. The record for 08-02 states it fits every category from ① to ⑥. A single lecture contained references to unapproved indications, unsupported claims, exaggerated language, and missing safety information all at once. Why do you think that happened?"

Yui"Because the internal review existed in name only. It wasn't functioning as a real checkpoint that actually examines the content."

Mio"Right. Internal review isn't a box to tick so a lecture can proceed. It has to work as the last line of defence that catches multiple problems before they reach the audience. Now look at 08-03. The phrase 'an abnormal situation' appears. Which provisions does that run into?"

Yui"It's inciting anxiety to push physicians to switch away from a competitor's product, so… PMD Act Article 66, prohibition of exaggerated advertising? And simultaneously a prohibited act under Guideline Principle (2) for disparaging another company's product?"

Mio"Both correct. That's why this case appears as a cross-reference under category 06-1 as well. Using fear to manipulate isn't just a rhetorical excess—it's treated as exaggerated advertising prohibited under Article 66. Last one: 08-04, the outdated package insert. Which provision makes that a problem?"

Yui"PMD Act Article 68-2, the obligation to provide information. There's a duty to supply accurate, up-to-date information, but they kept using a format that was superseded once the transition period ended."

Mio"Exactly. Looking at all four together, the location of the violation differs in each case, but the questions a reviewer must ask stay the same: Is this information current? How was it verified internally? Does the impression it creates in the recipient's mind fall within appropriate bounds? Even when a case lands in 'miscellaneous,' those three questions don't change."

4 real cases from the reports